Comparison Of Two Tablet Formulations Of SB-568859

Completed · Phase 1

Conditions studied: Atherosclerosis

In brief

SB-568859 is a medication that is being developed for the treatment of atherosclerosis (hardening of the arteries). The purpose of this study is to see if there is a difference in how the human body takes up the study drug depending on how the study drug is made. This study will compare SB-568859 tablets that are made in 2 different ways. This is not a treatment study.

Key facts

Study ID

NCT00470145

Run by

GlaxoSmithKline

People needed

28

Starts

2007-04-01

Expected to finish

2007-07-01

Last updated by the study team

2012-06-04

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men and sterile women between 18 and 50 years old
• Body weight greater than 50 pounds and a body mass index between 19 and 31
• Normal electrocardiogram

You may not qualify if…

• No history of asthma or severe allergic reactions
• No history of or current drug use
• No Hepatitis or HIV/AIDS
• No excessive alcohol use
• No smoking or tobacco use
• No use of prescription drugs, over-the-counter drugs or vitamins within 7 days
• No use of herbal supplements within 14 days
• No treatment with an investigational drug within 30 days.
• No treatment with 4 or more investigational drugs in the last 12 months
• No grapefruit or grapefruit juice in the last 7 days
• No donation of blood in the last 8 weeks
• No history of allergy to heparin
• No history of liver or gall bladder disease
• Unwillingness to use contraception

Where it is running

• GSK Investigational Site — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.